Tag Archive for: Cancer

iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib

/in

Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP Competitive Allosteric Modulator Of PI3Kδ, For The Potential Treatment Of Solid And Hematological Tumors Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the […]

Read more

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

/in

MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales  AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]

Read more

Leucid Bio provides business update and outlook for 2023

/in

Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]

Read more

Sequana Medical announces 2022 Full Year Results and 2023 Outlook

/in

alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]

Read more

Sequana Medical announces grant of additional DSR® patent in United States

/in

Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. Read more…

Read more